Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $135
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Blueprint Medicines and raises the price target from $133 to $135.
October 31, 2024 | 10:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating for Blueprint Medicines and increased the price target from $133 to $135, indicating a positive outlook.
The reaffirmation of a Buy rating and a slight increase in the price target by a reputable analyst suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100